Overview of the regulation of the class IA PI3K/AKT pathway by SUMO

被引：26
|
作者：
Vidal, Santiago [1 ]
Bouzaher, Yanis Hichem [1 ]
El Motiam, Ahmed [1 ,2 ,3 ]
Seoane, Rocio [1 ]
Rivas, Carmen [1 ,4 ]
机构：
[1] Univ Santiago De Compostela, Ctr Invest Med Mol & Enfermedades Cronicas CIMUS, Inst Invest Sanit IDIS, Santiago De Compostela 15706, Spain
[2] Univ Toronto, Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Dept Ophthalmol & Vis Sci,Sinai Hlth Syst, Toronto, ON M5G 1X5, Canada
[3] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X5, Canada
[4] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X5, Canada
来源：
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY | 2022年 / 132卷
关键词：
SUMO; PI3K; p85; p110; AKT; PTEN; NF-KAPPA-B; CELL-CYCLE PROGRESSION; PROTEIN-KINASE-B; E3; LIGASE; TUMOR-SUPPRESSOR; PHOSPHATIDYLINOSITOL; 3-KINASE; TYROSINE PHOSPHORYLATION; EMERGING MECHANISMS; RELA/P65; SUBUNIT; TOPORS FUNCTIONS;
D O I：
10.1016/j.semcdb.2021.10.012
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
The phosphatidylinositol-3-kinase (PI3K)/AKT pathway is a major regulator of metabolism, migration, survival, proliferation, and antiviral immunity. Both an overactivation and an inhibition of the PI3K/AKT pathway are related to different pathologies. Activation of this signaling pathway is tightly controlled through a multistep process and its deregulation can be associated with aberrant post-translational modifications including SUMOylation. Here, we review the complex modulation of the PI3K/AKT pathway by SUMOylation and we discuss its putative incvolvement in human disease.
引用
收藏
页码：51 / 61
页数：11
相关论文
共 50 条
  • [31] Activation of PI3Kγ/Akt pathway mediates bone cancer pain in rats
    Guan, Xuehai
    Fu, Qiaochu
    Xiong, Bingrui
    Song, Zhenpeng
    Shu, Bin
    Bu, Huilian
    Xu, Bing
    Manyande, Anne
    Cao, Fei
    Tian, Yuke
    JOURNAL OF NEUROCHEMISTRY, 2015, 134 (03) : 590 - 600
  • [32] Drugging the PI3K/AKT/mTOR Pathway in ER plus Breast Cancer
    Alves, Carla L.
    Ditzel, Henrik J.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (05)
  • [33] Targeting the PI3K/AKT/mTOR Signaling Pathway in Medulloblastoma
    Dimitrova, V.
    Arcaro, A.
    CURRENT MOLECULAR MEDICINE, 2015, 15 (01) : 82 - 93
  • [34] Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs
    Markman, Ben
    Dienstmann, Rodrigo
    Tabernero, Josep
    ONCOTARGET, 2010, 1 (07) : 530 - 543
  • [35] AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV
    Bhatt, Aadra P.
    Damania, Blossom
    FRONTIERS IN IMMUNOLOGY, 2013, 3
  • [36] PI3K Pathway Inhibitors: Better Not Left Alone
    Markman, Ben
    Tao, Jessica J.
    Scaltriti, Maurizio
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (05) : 895 - 906
  • [37] Oxygen-independent Regulation of HIF-1: Novel Involvement of PI3K/AKT/mTOR Pathway in Cancer
    Agani, Faton
    Jiang, Bing-Hua
    CURRENT CANCER DRUG TARGETS, 2013, 13 (03) : 245 - 251
  • [38] The PI3K/AKT Pathway and Renal Cell Carcinoma
    Huifang Guo
    Peter German
    Shanshan Bai
    Sean Barnes
    Wei Guo
    Xiangjie Qi
    Hongxiang Lou
    Jiyong Liang
    Eric Jonasch
    Gordon B.Mills
    Zhiyong Ding
    Journal of Genetics and Genomics, 2015, 42 (07) : 343 - 353
  • [39] The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin
    Stylianou, Kostas
    Petrakis, Ioannis
    Mavroeidi, Vasiliki
    Stratakis, Stavros
    Vardaki, Eleftheria
    Perakis, Kostas
    Stratigis, Spyros
    Passam, Andreas
    Papadogiorgaki, Eva
    Giannakakis, Kostas
    Nakopoulou, Lydia
    Daphnis, Eugene
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2011, 26 (02) : 498 - 508
  • [40] Targeting PI3K/AKT signaling pathway in obesity
    Savova, Martina S.
    Mihaylova, Liliya, V
    Tews, Daniel
    Wabitsch, Martin
    Georgiev, Milen I.
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 159
12345